NPCE NeuroPace, Inc.
USHealthcareAs of 2026-07-10 16:00
Why NPCE matters now
NeuroPace, Inc. (NPCE) is a US stock in Healthcare. The latest InvestLog snapshot shows $17.11 with +0.82% on the session and $583.3M in market capitalization; recent performance reads 1-month -1.39% and YTD +1.23%.
The latest financial table shown here is Q1 2026, with revenue of $22.1M, net income of $-6.7M, and EPS of $-0.20. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1.8%.
The latest indexable market news headline is "Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $20.00; recent insider activity includes Andrade Lisa filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
36.46
P/S
5.35
EV/EBITDA
-42.52
DCF Value
$-32.75
FCF Yield
-1.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
78.3%
Operating Margin
-16.8%
Net Margin
-21.7%
ROE
-120.7%
ROA
-21.8%
ROIC
-19.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $22.1M | $-6.7M | $-0.20 |
| Q4 2025 | $26.6M | $-2.7M | $-0.08 |
| FY 2025 | $100.0M | $-21.5M | $-0.66 |
| Q3 2025 | $27.4M | $-3.5M | $-0.11 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$20.00
Target (Median)
$20.00
Target Range
$20.00 - $20.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
1.88
NeuroPace, Inc. is a U.S.-based medical technology firm. It specializes in the creation and distribution of the RNS system, an advanced brain-responsive neuromodulation device designed to manage medically intractable focal epilepsy. This innovative system delivers tailored, real-time therapy directly to the source of seizures. Furthermore, the RNS system continuously records brain activity, providing medical professionals with the capability to monitor patients both on-site and remotely. The company supplies its devices to hospitals for both initial surgical implantations and subsequent replacement procedures. NeuroPace, Inc. was founded in 1997 and maintains its corporate headquarters in Mountain View, California.